MCID: CCC001
MIFTS: 60

Coccidioidomycosis

Categories: Rare diseases, Infectious diseases

Aliases & Classifications for Coccidioidomycosis

MalaCards integrated aliases for Coccidioidomycosis:

Name: Coccidioidomycosis 12 72 49 55 51 3 41 14 69
Valley Fever 49 55 40 3
Primary Extrapulmonary Coccidioidomycosis 12 69
Coccidiosis 49 69
Primary Pulmonary Coccidioidomycosis 69
Coccidioides Immitis Infection 49
San Joaquin Valley Fever 55
Acute Coccidioidomycosis 69
Coccidioides Infection 55
Enteric Coccidiosis 69
California Disease 55
San Joaquin Fever 49
Desert Rheumatism 55
Desert Fever 55

Characteristics:

Orphanet epidemiological data:

55
coccidioidomycosis
Inheritance: Not applicable; Age of onset: All ages;

Classifications:

Orphanet: 55  
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:13450
ICD10 32 B38 B38.9
ICD9CM 34 114 114.9
MeSH 41 D003047
NCIt 46 C84642
Orphanet 55 ORPHA228123
MESH via Orphanet 42 D003047
UMLS via Orphanet 70 C0009186 C0851907 C0153257

Summaries for Coccidioidomycosis

MedlinePlus : 40 Valley Fever is a disease caused by a fungus (or mold) called Coccidioides. The fungi live in the soil of dry areas like the southwestern U.S. You get it from inhaling the spores of the fungus. The infection cannot spread from person to person. Anyone can get Valley Fever. But it's most common among older adults, especially those 60 and older. People who have recently moved to an area where it occurs are at highest risk for infection. Other people at higher risk include Workers in jobs that expose them to soil dust. These include construction workers, agricultural workers, and military forces doing field training. African Americans and Asians Women in their third trimester of pregnancy People with weak immune systems Valley Fever is often mild, with no symptoms. If you have symptoms, they may include a flu-like illness, with fever, cough, headache, rash, and muscle aches. Most people get better within several weeks or months. A small number of people may develop a chronic lung or widespread infection. Valley Fever is diagnosed by testing your blood, other body fluids, or tissues. Many people with the acute infection get better without treatment. In some cases, doctors may prescribe antifungal drugs for acute infections. Severe infections require antifungal drugs. Centers for Disease Control and Prevention

MalaCards based summary : Coccidioidomycosis, also known as valley fever, is related to toxoplasmosis and prosthetic joint infection, and has symptoms including conjunctivitis, arthritis and chest pain. An important gene associated with Coccidioidomycosis is IFNGR1 (Interferon Gamma Receptor 1), and among its related pathways/superpathways are Innate Immune System and Toll-Like receptor Signaling Pathways. The drugs Valproic Acid and Bevacizumab have been mentioned in the context of this disorder. Affiliated tissues include lung, testes and skin, and related phenotypes are hematopoietic system and homeostasis/metabolism

Disease Ontology : 12 A primary systemic mycosis that results_in systemic fungal infection, has material basis in Coccidioides immitis, transmitted_by airborne spores and has symptom conjunctivitis, has symptom arthritis, has symptom chest pain and results_in_formation_of skin nodules.

CDC : 3 Valley fever, also called coccidioidomycosis, is an infection caused by the fungus Coccidioides. The fungus is known to live in the soil in the southwestern United States and parts of Mexico and Central and South America. The fungus was also recently found in south-central Washington. People can get Valley fever by breathing in the microscopic fungal spores from the air, although most people who breathe in the spores don’t get sick. Usually, people who get sick with Valley fever will get better on their own within weeks to months, but some people will need antifungal medication. Certain groups of people are at higher risk for becoming severely ill. It’s difficult to prevent exposure to Coccidioides in areas where it’s common in the environment, but people who are at higher risk for severe Valley fever should try to avoid breathing in large amounts of dust if they’re in these areas.

Wikipedia : 72 Coccidioidomycosis (/kɒkˌsɪdiɔɪdoʊmaɪˈkoʊsɪs/, kok-sid-ee-oy-doh-my-KOH-sis), commonly known as... more...

Related Diseases for Coccidioidomycosis

Diseases related to Coccidioidomycosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 149)
# Related Disease Score Top Affiliating Genes
1 toxoplasmosis 31.7 CD40LG TLR4
2 prosthetic joint infection 29.9 MBL2 TLR4
3 pneumonia 29.8 CD40LG MBL2 TLR4
4 cryptococcosis 29.6 CARD9 MBL2
5 meningoencephalitis 29.3 CARD9 CD40LG
6 mycobacterium tuberculosis 1 29.3 CD69 IFNGR1 MBL2 TLR4
7 candidiasis 28.8 CARD9 CLEC7A STAT1
8 rift valley fever 12.8
9 coccidiosis 12.3
10 cryptosporidiosis 11.3
11 sarcocystosis 11.2
12 cyclosporiasis 10.9
13 cystoisosporiasis 10.9
14 neisseria meningitidis infection 10.3 MBL2 TLR4
15 campylobacteriosis 10.3 STAT1 TLR4
16 typhoid fever 10.3 IFNGR1 TLR4
17 lymphadenitis 10.2 IFNGR1 TLR4
18 trench fever 10.2 CD40LG TLR4
19 immunoglobulin g deficiency 10.2 CD40LG MBL2
20 pyelitis 10.2 CD40LG TLR4
21 periodontosis 10.1 CD40LG TLR4
22 legionnaires' disease 10.1 CD40LG TLR4
23 bacteriuria 10.1 CD40LG TLR4
24 encephalitis 10.1
25 hemorrhagic fever 10.1
26 immunoglobulin alpha deficiency 10.1 CD40LG MBL2
27 scrub typhus 10.1 CD40LG TLR4
28 zika fever 10.1 CD40LG STAT1
29 axillary adenitis 10.1 CD40LG STAT1
30 middle ear disease 10.1 CD40LG TLR4
31 q fever 10.1 CD40LG TLR4
32 streptococcal meningitis 10.1 CD40LG MBL2
33 pelvic inflammatory disease 10.1 CD40LG TLR4
34 histoplasmosis 10.1
35 legionellosis 10.1 CD40LG TLR4
36 idiopathic neutropenia 10.1 CD40LG TLR4
37 rheumatic fever 10.1 CD40LG MBL2
38 brucellosis 10.1 CD40LG TLR4
39 norwegian scabies 10.1 CD40LG STAT1
40 salmonellosis 10.1 IFNGR1 STAT1 TLR4
41 dengue disease 10.1 CD40LG MBL2
42 crimean-congo hemorrhagic fever 10.1
43 immunodeficiency with hyper-igm, type 3 10.1 CARD9 CD40LG
44 progressive multifocal leukoencephalopathy 10.1 CD40LG STAT1
45 blastomycosis 10.0
46 meningitis 10.0
47 hepatitis b 10.0 MBL2 STAT1 TLR4
48 helicobacter pylori infection 10.0 IFNGR1 TLR4
49 dengue hemorrhagic fever 10.0 CD40LG STAT1
50 vulvovaginal candidiasis 10.0 CLEC7A MBL2

Graphical network of the top 20 diseases related to Coccidioidomycosis:



Diseases related to Coccidioidomycosis

Symptoms & Phenotypes for Coccidioidomycosis

Symptoms:

12
  • conjunctivitis
  • arthritis
  • chest pain

UMLS symptoms related to Coccidioidomycosis:


pruritus, fever

MGI Mouse Phenotypes related to Coccidioidomycosis:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.76 CARD9 CD40LG CD69 CLEC7A IFNGR1 MBL2
2 homeostasis/metabolism MP:0005376 9.5 CARD9 CD40LG CLEC7A IFNGR1 MBL2 STAT1
3 immune system MP:0005387 9.23 CARD9 CD40LG CD69 CLEC7A IFNGR1 MBL2

Drugs & Therapeutics for Coccidioidomycosis

Drugs for Coccidioidomycosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 97)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Valproic Acid Approved, Investigational Phase 4 99-66-1 3121
2
Bevacizumab Approved, Investigational Phase 4 216974-75-3
3
Fluconazole Approved, Investigational Phase 4,Phase 3 86386-73-4 3365
4
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 22916-47-8 4189
5
Levoleucovorin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 68538-85-2
6
Pyrimethamine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 58-14-0 4993
7
Spiramycin Approved Phase 4,Phase 3,Phase 1 24916-50-5
8
Sulfadiazine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 68-35-9 5215
9
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 59-30-3 6037
10
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 58-05-9 143 6006
11 Anti-Infective Agents Phase 4,Phase 3,Phase 1,Phase 2
12 Antiparasitic Agents Phase 4,Phase 3,Phase 1,Phase 2
13 Anticonvulsants Phase 4
14 Antimanic Agents Phase 4
15 Central Nervous System Depressants Phase 4
16 GABA Agents Phase 4
17 Neurotransmitter Agents Phase 4,Phase 2
18 Psychotropic Drugs Phase 4,Phase 2
19 Tranquilizing Agents Phase 4
20 Angiogenesis Inhibitors Phase 4,Phase 1,Phase 2
21 Angiogenesis Modulating Agents Phase 4,Phase 1,Phase 2
22 Antifungal Agents Phase 4,Phase 3,Phase 1,Phase 2
23 Cytochrome P-450 CYP2C9 Inhibitors Phase 4,Phase 3,Phase 1
24 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
25 Hormone Antagonists Phase 4,Phase 3
26 Hormones Phase 4,Phase 3
27 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3
28 Steroid Synthesis Inhibitors Phase 4,Phase 3
29 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
30 Antidotes Phase 4,Phase 2,Phase 1
31 Antimalarials Phase 4,Phase 3,Phase 2,Phase 1
32 Antiprotozoal Agents Phase 4,Phase 3,Phase 1,Phase 2
33 Bone Density Conservation Agents Phase 4,Phase 1
34 Calcium, Dietary Phase 4,Phase 2,Phase 1
35 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1
36 Micronutrients Phase 4,Phase 1
37 Protective Agents Phase 4,Phase 2,Phase 1
38 Trace Elements Phase 4,Phase 1
39 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1
40 Vitamins Phase 4,Phase 1
41 Folate Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1
42 Vitamin B9 Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1
43
Nitazoxanide Approved, Investigational, Vet_approved Phase 3,Phase 1,Phase 2 55981-09-4 41684
44
Posaconazole Approved, Investigational, Vet_approved Phase 3 171228-49-2 147912
45
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
46
Sulfamethoxazole Approved Phase 3 723-46-6 5329
47
Trimethoprim Approved, Vet_approved Phase 3 738-70-5 5578
48 Renal Agents Phase 3
49 Trimethoprim, Sulfamethoxazole Drug Combination Phase 3
50
Atovaquone Approved Phase 2,Phase 1 95233-18-4 74989

Interventional clinical trials:

(show top 50) (show all 59)

# Name Status NCT ID Phase Drugs
1 Pilot Trial of Valproate as Adjunctive Treatment for Toxoplasma Gondii Infection in Early Course Schizophrenia Completed NCT02011750 Phase 4 Sodium Valproate treatment;Placebo
2 Intravitreal Bevacizumab in Recalcitrant Inflammatory Ocular Neovascularization Completed NCT00645697 Phase 4
3 Early Fluconazole Treatment for Coccidiodomycosis Pneumonia Recruiting NCT02663674 Phase 4 Fluconazole
4 Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis Recruiting NCT00004317 Phase 4 Leucovorin calcium;Pyrimethamine;Spiramycin;Sulfadiazine
5 Assessment of Two Therapeutic Strategies in the Treatment of Children With Congenital Toxoplasmosis Unknown status NCT01202500 Phase 3
6 POS vs FLU for First Line Treatment of Coccidioidomycosis (Study P04558Am1)(COMPLETED) Completed NCT00423267 Phase 3 Posaconazole;Fluconazole
7 A Multi-center Study of Spherule-Derived Coccidioidin Completed NCT00690092 Phase 3
8 Randomized Comparative Study of Fluconazole Versus Clotrimazole Troches in the Prevention of Serious Fungal Infection in Patients With AIDS or Advanced AIDS-Related Complex. (A Nested Study of ACTG 081) Completed NCT00000676 Phase 3 Clotrimazole;Fluconazole
9 Prevention of Congenital Toxoplasmosis With Pyrimethamine + Sulfadiazine Versus Spiramycine During Pregnancy Completed NCT01189448 Phase 3 Pyrimethamine/Sulfadiazine;Spiramycine
10 Influence of Trimethoprim-Sulfamethoxazole for the Recurrence of Ocular Toxoplasmosis Completed NCT01449877 Phase 3 Trimethoprim-Sulfamethoxazole
11 Safety and Effectiveness of Nitazoxanide for the Treatment of Cryptosporidiosis in AIDS Patients Terminated NCT00004986 Phase 3 Nitazoxanide
12 Safety/Immunogenicity/Genetic Drift of MP-12 Rift Valley Fever Vaccine Completed NCT00415051 Phase 2
13 Safety and Immunogenicity Study of Rift Valley Fever Vaccine Completed NCT00584194 Phase 2
14 Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants Completed NCT00289185 Phase 2
15 Double-blind Study of Safety and Immunogenicity of Two Candidate Malaria Vaccines in Gabonese Children Completed NCT00307021 Phase 2
16 Nitazoxanide for the Treatment of Chronic Diarrhea in HIV Infected Children Completed NCT00055107 Phase 1, Phase 2 Nitazoxanide
17 A Study of Nitazoxanide in Patients With AIDS and Diarrhea Caused by Cryptosporidium Completed NCT00001081 Phase 2 Nitazoxanide
18 Phase II Randomized Open-Label Trial of Atovaquone Plus Pyrimethamine and Atovaquone Plus Sulfadiazine for the Treatment of Acute Toxoplasmic Encephalitis Completed NCT00000794 Phase 2 Sulfadiazine;Clarithromycin;Atovaquone;Pyrimethamine;Leucovorin calcium
19 A Double-Blind, Placebo-Controlled Trial of Paromomycin for Treatment of Cryptosporidiosis in Patients With Advanced HIV Disease and CD4 Counts Under 150 Cells/mm3 Completed NCT00000771 Phase 2 Paromomycin sulfate
20 Primary Prophylaxis of Cerebral Toxoplasmosis in HIV-Infected Patients Completed NCT00000643 Phase 2 Pyrimethamine;Leucovorin calcium
21 Safety and Immunogenicity Study of Rift Valley Fever Vaccine, Inactivated Enrolling by invitation NCT00869713 Phase 2
22 Sertraline in Addition to Standard of Care Treatment for Coccidioidomycosis Not yet recruiting NCT02908334 Phase 2 Sertraline
23 A Phase 2A Evaluation of the Safety, Tolerability, Pharmacokinetics, Efficacy of Clofazimine (CFZ) in Cryptosporidiosis Not yet recruiting NCT03341767 Phase 2 Clofazimine;Placebo
24 Safety and PK of Nikkomycin Z for Coccidioides Pneumonia Treatment Terminated NCT00614666 Phase 1, Phase 2 nikkomycin Z
25 Interleukin 12 (IL-12) for the Treatment of Cryptosporidiosis in AIDS Patients Terminated NCT00057486 Phase 1, Phase 2 IL-12
26 Phase I Study of Pyrimethamine in Healthy Japanese and Caucasian Subjects Completed NCT03258762 Phase 1 Pyrimethamine;Calcium folinate
27 Antiretroviral Drug Interaction Study in Volunteers With HIV Completed NCT01479361 Phase 1 Atovaquone 750 mg twice daily;Atovaquone 1500 mg twice daily
28 A Randomized, Multicenter, Double-Blind, Parallel-Group, Placebo-Controlled Trial of the Efficacy and Safety of Bovine Anti-Cryptosporidium Immunoglobulin (BACI) in the Treatment of Cryptosporidium Enteritis in AIDS Patients Completed NCT00002248 Phase 1 Cryptosporidium Immune Whey Protein Concentrate (Bovine)
29 A Study of Letrazuril in the Treatment of AIDS-Related Diarrhea Completed NCT00001018 Phase 1 Letrazuril
30 A Study of Spiramycin in the Treatment of Patients With AIDS-Related Diarrhea Completed NCT00000980 Phase 1 Spiramycin
31 A Study of Pyrimethamine in the Treatment of Infection by a Certain Parasite in HIV-Positive Patients Completed NCT00000973 Phase 1 Pyrimethamine;Leucovorin calcium;Zidovudine
32 A Study of Azithromycin Plus Pyrimethamine in the Treatment of a Brain Infection in Patients With AIDS Completed NCT00000966 Phase 1 Azithromycin;Pyrimethamine;Leucovorin calcium
33 A Study to Evaluate the Use of Nitazoxanide to Treat Cryptosporidiosis Unknown status NCT00002158 Nitazoxanide
34 Risk of Coccidioidomycosis in Patients Receiving Anti-TNF and Other Biologic Agents for an Inflammatory Arthritis Completed NCT00796809
35 Rift Valley Fever in Kenya Completed NCT00287014
36 A Study of Fluconazole in the Prevention of Fungal Infections in HIV-Infected Patients Living in Areas Where Fungal Infections Are Common Completed NCT00002325 Fluconazole
37 Open, Non-Comparative Study of Fluconazole in Patients With Coccidioidal Meningitis Completed NCT00002010 Fluconazole
38 Cerebral Toxoplasmosis and AIDS Completed NCT00803621
39 Evaluation of Biological Biomarkers Diagnostic of Toxoplasmosis Uveitis Completed NCT02843438 Anti-toxoplasmosis treatment;Anti-inflammatory treatments
40 Breast Milk Composition and HIV-exposed/Unexposed Early Infant Growth and Infectious Disease Events Completed NCT01699841
41 Trial of Ceramic Water Filters to Reduce Cryptosporidium Infection in Kenya Completed NCT01695304
42 Transmission and the Respiratory Tract in Cryptosporidiosis Completed NCT00507871
43 Azithromycin in the Treatment of Cryptosporidiosis in Patients Who Have Not Had Success With Other Drugs Completed NCT00002328 Azithromycin
44 A 28-Day Study of Diclazuril in the Treatment of Cryptosporidiosis in Patients With AIDS Completed NCT00002278 Diclazuril
45 The Effectiveness of Cow's Milk Immune Globulin in the Treatment of AIDS-Related Diarrhea Completed NCT00002264 Cryptosporidium Immune Whey Protein Concentrate (Bovine)
46 Azithromycin in the Treatment of Cryptosporidiosis in Patients With Acquired Immune Deficiency Syndrome (AIDS): A Randomized, Multi-Center, Placebo-Controlled, Double-Blind Study Completed NCT00002082 Azithromycin
47 Toxoplasmic Encephalitis in Patients With AIDS. Treatment and Prevention of Relapse Completed NCT00002064 Pyrimethamine;Clindamycin
48 Open-Label "Compassionate" Use Study of Spiramycin for the Treatment of Diarrhea Due to Chronic Cryptosporidiosis in Immunocompromised Patients Completed NCT00002062 Spiramycin
49 Protocol For the Treatment of Cryptosporidiosis in AIDS Patients With Diclazuril (R64,433) Completed NCT00002027 Diclazuril
50 A Pilot Study of 566C80 for the Salvage Treatment of Toxoplasmic Encephalitis in Patients Infected With the Human Immunodeficiency Virus (HIV) Who Have Failed or Are Intolerant of Pyrimethamine-Sulfadiazine Completed NCT00001994 Atovaquone

Search NIH Clinical Center for Coccidioidomycosis

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: coccidioidomycosis

Genetic Tests for Coccidioidomycosis

Anatomical Context for Coccidioidomycosis

MalaCards organs/tissues related to Coccidioidomycosis:

38
Lung, Testes, Skin, Liver, Brain, Bone, Prostate

Publications for Coccidioidomycosis

Articles related to Coccidioidomycosis:

(show top 50) (show all 1284)
# Title Authors Year
1
Coccidioidomycosis for Neurosurgeons. ( 29107717 )
2018
2
Vector competence of Culex antennatus and Anopheles coustani mosquitoes for Rift Valley fever virus in Madagascar. ( 29383746 )
2018
3
Seroprevalence of Rift Valley Fever Virus Antibodies in Cattle in Mali, 2005-2014. ( 29363462 )
2018
4
The Novel Fungal Cyp51 Inhibitor VT-1598 is Efficacious in Experimental Models of Central Nervous System Coccidioidomycosis Caused by<i>Coccidioides posadasii</i>and<i>Coccidioides immitis</i>. ( 29437615 )
2018
5
Phosphoproteomic analysis reveals Smad protein family activation following Rift Valley fever virus infection. ( 29408900 )
2018
6
Datasets for mapping pastoralist movement patterns and risk zones of Rift Valley fever occurrence. ( 29276743 )
2018
7
Experimental transmission of West Nile Virus and Rift Valley Fever Virus by Culex pipiens from Lebanon. ( 29324834 )
2018
8
Anti-Rift Valley fever virus activity in vitro, pre-clinical pharmacokinetics and oral bioavailability of benzavir-2, a broad-acting antiviral compound. ( 29386590 )
2018
9
Role of modified Eloesser flap in the treatment of bronchopleural fistula caused by pulmonary coccidioidomycosis. ( 29351943 )
2018
10
Coccidioidomycosis: Imported and Possible Domestic Cases in China A Case Report and Review, 1958-2017. ( 29383771 )
2018
11
What's New in Spinal Coccidioidomycosis? ( 29129768 )
2018
12
Combined Endosonography Reduces Time to Diagnose Pulmonary Coccidioidomycosis. ( 29346251 )
2018
13
Ecological distribution and population dynamics of Rift Valley fever virus mosquito vectors (Diptera, Culicidae) in Senegal. ( 29316967 )
2018
14
Peripheral Blood Biomarkers of Disease Outcome in a Monkey Model of Rift Valley Fever Encephalitis. ( 29118127 )
2018
15
Understanding the legal trade of cattle and camels and the derived risk of Rift Valley Fever introduction into and transmission within Egypt. ( 29351273 )
2018
16
A point-source outbreak of Coccidioidomycosis among a highway construction crew. ( 29053941 )
2018
17
Rift Valley Fever in Egypt and other African countries: Historical review, recent outbreaks and possibility of disease occurrence in Egypt. ( 29391128 )
2018
18
Disseminated coccidioidomycosis-related cervical intramedullary lesion causing quadriplegia in an immunocompetent host. ( 29237660 )
2017
19
Single-center experience of antifungal prophylaxis for coccidioidomycosis in heart transplant recipients within an endemic area. ( 28695649 )
2017
20
Large-Scale Land Development, Fugitive Dust, and Increased Coccidioidomycosis Incidence in the Antelope Valley of California, 1999-2014. ( 28084574 )
2017
21
Coccidioidomycosis, immunoglobulin deficiency: safety challenges with CAR T cells therapy for relapsed lymphoma. ( 29032736 )
2017
22
Recurrence of cutaneous coccidioidomycosis 6 years after valley fever: A case presentation and literature review. ( 28811115 )
2017
23
Rift Valley Fever Seroprevalence in Coastal Kenya. ( 28719329 )
2017
24
Diagnosis of coccidioidomycosis in a non-endemic area: Inference of the probable geographic area of an infection. ( 28784311 )
2017
25
Spinal coccidioidomycosis: A current review of diagnosis and management. ( 28844921 )
2017
26
Genetic stability of Rift Valley fever virus MP-12 vaccine during serial passages in culture cells. ( 29167748 )
2017
27
Detection of the Northeastern African Rift Valley Fever Virus Lineage During the 2015 Outbreak in Mauritania. ( 28638845 )
2017
28
ENHANCED ANTIBODY DETECTION AND DIAGNOSIS OF COCCIDIOIDOMYCOSIS WITH THE MIRAVISTA IGG AND IGM DETECTION ENZYME IMMUNOASSAY. ( 28053216 )
2017
29
Distinct virulence of Rift Valley fever phlebovirus strains from different genetic lineages in a mouse model. ( 29267298 )
2017
30
Seroepidemiological Survey of Rift Valley Fever Virus in Ruminants in Garissa, Kenya. ( 27929928 )
2017
31
Coccidioidomycosis Involving Lungs and Skin: A Mimicker of Metastatic Disease. ( 28857979 )
2017
32
Rift Valley fever virus and European mosquitoes: vector competence of Culex pipiens and Stegomyia albopicta (=a88Aedes albopictus). ( 28782121 )
2017
33
Immune Reconstitution Inflammatory Syndrome in Patients with AIDS and Disseminated Coccidioidomycosis: A Case Series and Review of the Literature. ( 28911256 )
2017
34
Relating coccidioidomycosis (valley fever) incidence to soil moisture conditions. ( 29124249 )
2017
35
Drivers for Rift Valley fever emergence in Mayotte: A Bayesian modelling approach. ( 28732006 )
2017
36
Reconstruction of Rift Valley fever transmission dynamics in Madagascar: estimation of force of infection from seroprevalence surveys using Bayesian modelling. ( 28051125 )
2017
37
Fluoroquinolone therapy could influence the clinical signs of pulmonary coccidioidomycosis. ( 28081876 )
2017
38
Alterations in the host transcriptome in vitro following Rift Valley fever virus infection. ( 29085037 )
2017
39
Sorafenib impedes Rift Valley fever virus egress by inhibiting Valosin-containing protein function in the cellular secretory pathway. ( 28794043 )
2017
40
What to Do for the Asymptomatic Pulmonary Coccidioidal Nodule or Cavity in Immunosuppressed Patients? A Focus in the Recent Coccidioidomycosis Guidelines. ( 27986674 )
2017
41
The first serological evidence for Rift Valley fever infection in the camel, goitered gazelle and Anatolian water buffaloes in Turkey. ( 28861841 )
2017
42
Arthroconidia in Lung Tissue: An Unusual Histopathological Finding in Pulmonary Coccidioidomycosis. ( 28778515 )
2017
43
Transmission of Rift Valley fever virus from European-breed lambs to Culex pipiens mosquitoes. ( 29281642 )
2017
44
Coccidioidomycosis: An underreported cause of death-Arizona, 2008-2013. ( 28595294 )
2017
45
Inter-epidemic Rift Valley fever virus seroconversions in an irrigation scheme in Bura, south-east Kenya. ( 28710814 )
2017
46
Wetlands, wild Bovidae species richness and sheep density delineate risk of Rift Valley fever outbreaks in the African continent and Arabian Peninsula. ( 28742814 )
2017
47
Notes from the Field: Increase in Coccidioidomycosis - California, 2016. ( 28796756 )
2017
48
Disseminated coccidioidomycosis presenting with intramedullary spinal cord abscesses: Management challenges. ( 28053850 )
2017
49
Colorimetric Detection of Unamplified Rift Valley Fever Virus Genetic Material Using Unmodified Gold Nanoparticles. ( 28918558 )
2017
50
Testing for coccidioidomycosis in emergency departments in Arizona. ( 29228363 )
2017

Variations for Coccidioidomycosis

Expression for Coccidioidomycosis

Search GEO for disease gene expression data for Coccidioidomycosis.

Pathways for Coccidioidomycosis

Pathways related to Coccidioidomycosis according to GeneCards Suite gene sharing:

(show all 21)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.6 CARD9 CD40LG CLEC7A IFNGR1 MBL2 STAT1
2
Show member pathways
12.6 CARD9 CLEC7A STAT1 TLR4
3
Show member pathways
12.37 CD40LG IFNGR1 STAT1
4
Show member pathways
12.3 IFNGR1 STAT1 TLR4
5
Show member pathways
12.27 IFNGR1 STAT1 TLR4
6 12.25 CARD9 CD40LG STAT1
7
Show member pathways
12.2 IFNGR1 STAT1 TLR4
8
Show member pathways
11.87 IFNGR1 STAT1 TLR4
9
Show member pathways
11.85 IFNGR1 STAT1 TLR4
10
Show member pathways
11.76 IFNGR1 STAT1 TLR4
11 11.72 IFNGR1 STAT1 TLR4
12 11.61 CLEC7A MBL2 TLR4
13
Show member pathways
11.54 IFNGR1 STAT1
14
Show member pathways
11.53 CD40LG IFNGR1 STAT1 TLR4
15 11.42 CD40LG TLR4
16
Show member pathways
11.35 IFNGR1 STAT1 TLR4
17 11.29 CD40LG CD69
18 11.27 CARD9 CLEC7A IFNGR1 STAT1 TLR4
19 11.24 CD40LG TLR4
20 11.08 IFNGR1 STAT1
21 11 CD40LG TLR4

GO Terms for Coccidioidomycosis

Cellular components related to Coccidioidomycosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 8.8 CD40LG CD69 TLR4

Biological processes related to Coccidioidomycosis according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 innate immune response GO:0045087 9.62 CARD9 CLEC7A MBL2 TLR4
2 immune system process GO:0002376 9.56 CARD9 CLEC7A MBL2 TLR4
3 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.49 CARD9 TLR4
4 positive regulation of tumor necrosis factor production GO:0032760 9.48 CARD9 TLR4
5 positive regulation of interleukin-6 production GO:0032755 9.46 CARD9 TLR4
6 positive regulation of interleukin-12 production GO:0032735 9.43 CD40LG TLR4
7 positive regulation of interleukin-10 production GO:0032733 9.4 CD40LG TLR4
8 positive regulation of stress-activated MAPK cascade GO:0032874 9.37 CARD9 TLR4
9 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.16 STAT1 TLR4
10 regulation of interferon-gamma-mediated signaling pathway GO:0060334 8.96 IFNGR1 STAT1
11 positive regulation of interferon-alpha production GO:0032727 8.62 STAT1 TLR4

Molecular functions related to Coccidioidomycosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 tumor necrosis factor receptor binding GO:0005164 8.96 CD40LG STAT1
2 carbohydrate binding GO:0030246 8.8 CD69 CLEC7A MBL2

Sources for Coccidioidomycosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....